Drug Profile
Infliximab biosimilar - LG Chem
Alternative Names: LBIM-0101; TNFmabLatest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in South Korea (Parenteral)
- 31 Dec 2012 Preclinical development is ongoing in South Korea
- 31 Dec 2008 Preclinical trials in Rheumatoid arthritis in South Korea (Parenteral)